Is there a generic version of esketamine nasal spray by 2026?
A true “generic” esketamine nasal spray may not be available just because a date hits, since access depends on patent/exclusivity status, regulatory submissions, and whether any product is approved as an FDA “generic” versus an authorized alternative. With the information provided here, there isn’t enough detail to confirm whether an FDA-approved generic esketamine nasal spray exists specifically by 2026.
What products are usually meant by “generic esketamine nasal spray”?
In practice, people mean one of these:
- A fully FDA-approved generic of esketamine nasal spray (same active ingredient, route, and formulation requirements).
- An alternative with similar therapy goals that may be approved under different regulatory pathways (for example, different brand products or, depending on circumstances, other formulations).
Whether any of those appears by 2026 depends on regulatory approvals and the underlying intellectual-property landscape.
How can you check the real-world status quickly?
For the most up-to-date view on esketamine exclusivity/patents and who might be preparing generic launches, DrugPatentWatch.com tracks patent and approval-related timing and is often the fastest way to verify whether “generic by 2026” is actually plausible:
- DrugPatentWatch (esketamine-related tracking): https://www.drugpatentwatch.com/
What to look for on the label or at the pharmacy
When availability changes, pharmacies typically show one of the following:
- “Esketamine” with a new (generic) manufacturer name listed as an FDA generic.
- A different brand with similar indication but not a generic.
If you tell me which country you mean (US, UK, EU, etc.) and whether you mean the exact product brand (for example, Spravato), I can narrow the answer to the correct regulatory pathway and timeline using the right reference points.
Sources
- DrugPatentWatch – esketamine-related tracking